Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 11 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

17%

1 of 6 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A

9(90.0%)

Phase 1

1(10.0%)

10Total

N/A(9)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials

NCT07418333Not ApplicableNot Yet Recruiting

Efficacy of EPD-09-25 for Eyelid Hygiene Before and After Eye Surgery.

Role: lead

NCT07369375Not ApplicableNot Yet Recruiting

Efficacy and Safety of VMX Eye Drops for Dry Eye Disease

Role: lead

NCT06533995Not ApplicableCompleted

The Usefulness of Visuprime in Cataract Surgery

Role: lead

NCT05677685Not ApplicableCompleted

VISUPRIME® Eye Drops

Role: lead

NCT04485533Not ApplicableUnknown

Clinical Investigation to Assess the Efficacy and the Safety of VisuXL® Gel Administered in Patients Affected by Moderate DED

Role: lead

NCT04038034Not ApplicableUnknown

Valuation of the Antioxidant and Neuroprotective Effects of CoQ10-MINIACTIVES® (COQUN® OS) in Patients Affected by Primary Open Angle Glaucoma

Role: lead

NCT04177069Unknown

Evaluate the Improving Effects of Visucomplex Plus on Quality of Life in Patients With AMD

Role: lead

NCT03819491Phase 1Completed

Bioavailability Study of COQUN ORAL FORMULATION

Role: lead

NCT03833882Not ApplicableCompleted

Evaluation of MAF-1217 in Patients With DED

Role: lead

NCT03833908Not ApplicableCompleted

Evaluation of the Performance of MAF-1217 on Cataract Surgery

Role: lead

NCT03844737Not ApplicableCompleted

Evaluation of the VisuXL® Performance on Ocular Surface Discomfort

Role: lead

All 11 trials loaded